CREBBP and acute myeloid leukemia: Notably, the cytotoxic effects of p300/CBP inhibitors on the FLT3-ITD+ AML patient samples were comparable to those observed in the AML cell lines MV-4-11 and MOLM-13, whereas quizartinib exhibited relatively weaker activity in the AML patient samples (Fig. 6c).